Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab responded to treatment with melflufen, according to interim data...
Selinexor Induces Deep Responses in Refractory Multiple Myeloma
More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a combination of selinexor and low-dose dexamethasone, according to results...
Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?
The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...
Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma?
Adding daratumumab to standard combination of lenalidomide and dexamethasone (Rd) reduced the risk of disease progression and death by 44 percent in patients with...
FDA Approves Elotuzumab-Based Triplet Regimen for Myeloma
The FDA approved the combination of elotuzumab plus pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM)...
FDA Approves Once-Weekly Carfilzomib Combo for Relapsed or Refractory MM
The FDA has approved a combination of once-weekly carfilzomib with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM). This...
Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
FDA Approves NGS-Based Test for Patients With ALL or MM
The FDA authorized the next-generation sequencing (NGS)–based ClonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukemia (ALL)...
BCMA-Targeting CAR T-Cell Therapy Shows High Response Rate in Pretreated Myeloma
Multiple myeloma (MM) is a potential target for chimeric antigen receptor (CAR) T-cell therapies, according to final results from a first-in-human trial of B-cell...
In Myeloma, Cure or Control?
Over the past two decades, the U.S. Food and Drug Administration (FDA) has approved a number of new treatments for patients with myeloma –...
Current Issue
February 2019, Volume 5, Issue 3
This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.
